| abstract |
The compounds and their pharmaceutically acceptable salts are useful as tachykinin inhibitors that act at the NK1, NK2 and NK3 receptors or a combination of two or more of them. They have the formula wherein A is CO, SO 2 or CH 2; Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, C1-6 alkoxy optionally substituted by one or more halogen and C1-6 alkyl optionally substituted with one or more halogen; X1 is C3-7 cycloalkyl, aryl or C1-6 alkyl, said C1-6 alkyl being optionally substituted with fluoro, CO2H, CO2 (C1-4alkyl), C3-7cycloalkyl, adamantyl, aryllylhet, and said C3-7 cycloalkyl is optionally substituted with one or two substituents each independently selected from C1-4 alkyl, C3-7 cycloalkyl, C1-4 alkoxy, OH, F, fluoro (C1-4 alkyl), and fluoro (C1 -4-alkoxy); X is a direct bond or NR1; R 6 SO 2 aryl, SO 2 (C 1-6 alkyl optionally substituted by one or more halogen), N (a) or (b). |